Identification of mouse cathepsin K structural elements that regulate the potency of odanacatib

Biochemical Journal

Volumn 474, Issue 5, 2017, Pages 851-864

  Law, Simon ^a   Andrault, Pierre Marie ^a   Aguda, Adeleke H ^a   Nguyen, Nham T ^a   Kruglyak, Natasha ^a   Brayer, Gary D ^a   Brömme, Dieter ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BALICATIB; CATHEPSIN K; ODANACATIB; BENZAMIDE DERIVATIVE; BIPHENYL DERIVATIVE; BONE DENSITY CONSERVATION AGENT; LIGAND; PIPERAZINE DERIVATIVE; PROTEIN BINDING; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN;

ARTICLE; CRYSTALLIZATION; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; HUMAN; KINETICS; METABOLISM; MOLECULAR CLONING; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; STRUCTURAL HOMOLOGY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; BENZAMIDES; BINDING SITES; BIPHENYL COMPOUNDS; BONE DENSITY CONSERVATION AGENTS; CATHEPSIN K; CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; KINETICS; LIGANDS; MICE; MUTAGENESIS, SITE-DIRECTED; PIPERAZINES; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 85014629423     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BCJ20160985     Document Type: Article

References (42)

1. 2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol. Chem. Hoppe-Seyler 376, 379-384 doi:10.1515/bchm3.1995.376.6.379
2. 2 in Spodoptera frugiperda and characterization of the enzyme. J. Biol. Chem. 271, 2126-2132 doi:10.1074/jbc.271.4.2126
3. Drake, F.H., Dodds, R.A., James, I.E., Connor, J.R., Debouck, C., Richardson, S. et al. (1996) Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271, 12511-12516 doi:10.1074/jbc.271.21.12511
4. Bromme, D. (2001) Papain-like cysteine proteases. Curr. Protoc. Protein Sci. Chapter 21, Unit 21.2 doi:10.1002/0471140864.ps2102s21
5. Aguda, A.H., Panwar, P., Du, X., Nguyen, N.T., Brayer, G.D. and Brömme, D. (2014) Structural basis of collagen fiber degradation by cathepsin K. Proc. Natl Acad. Sci. U.S.A. 111, 17474-17479 doi:10.1073/pnas.1414126111
6. Brömme, D. and Lecaille, F. (2009) Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin. Invest. Drugs 18, 585-600 doi:10.1517/13543780902832661
7. Costa, A.G., Cusano, N.E., Silva, B.C., Cremers, S. and Bilezikian, J.P. (2011) Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat. Rev. Rheumatol. 7, 447-456 doi:10.1038/nrrheum.2011.77
8. Becker, D.J., Kilgore, M.L. and Morrisey, M.A. (2010) The societal burden of osteoporosis. Curr. Rheumatol. Rep. 12, 186-191 doi:10.1007/s11926-010-0097-y
9. Brömme, D., Panwar, P. and Turan, S. (2016) Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: commonalities and differences. Expert Opin. Drug Discovery 11, 457-472 doi:10.1517/17460441.2016.1160884
10. Jee, W.S. and Yao, W. (2001) Overview: animal models of osteopenia and osteoporosis. J. Musculoskelet. Neuronal Interact. 1, 193-207 PMID:15758493
11. Komori, T. (2015) Animal models for osteoporosis. Eur. J. Pharmacol. 759, 287-294 doi:10.1016/j.ejphar.2015.03.028
12. Desmarais, S., Black, W.C., Oballa, R., Lamontagne, S., Riendeau, D., Tawa, P. et al. (2008) Effect of cathepsin K inhibitor basicity on in vivo off-target activities. Mol. Pharmacol. 73, 147-156 doi:10.1124/mol.107.039511
13. Desmarais, S., Massé, F. and Percival, M.D. (2009) Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools. Biol. Chem. 390, 941-948 doi:10.1515/BC.2009.092
14. Linnevers, C.J., McGrath, M.E., Armstrong, A., Mistry, F.R., Barnes, M.G., Klaus, J.L. et al. (1997) Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex. Protein Sci. 6, 919-921 doi:10.1002/pro.5560060421
15. Nallaseth, F.S., Lecaille, F., Li, Z. and Bromme, D. (2013) The role of basic amino acid surface clusters on the collagenase activity of cathepsin K. Biochemistry 52, 7742-7752 doi:10.1021/bi401051j
16. Battye, T.G.G., Kontogiannis, L., Johnson, O., Powell, H.R. and Leslie, A.G.W. (2011) iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. Sect. D Biol. Crystallogr. 67, 271-281 doi:10.1107/S0907444910048675
17. Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R. et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr. Sect. D Biol. Crystallogr. 67, 235-242 doi:10.1107/S0907444910045749
18. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C. and Read, R.J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 doi:10.1107/S0021889807021206
19. Moriarty, N.W., Grosse-Kunstleve, R.W. and Adams, P.D. (2009) Electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr. Sect. D Biol. Crystallogr. 65, 1074-1080 doi:10.1107/S0907444909029436
20. Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N. et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 213-221 doi:10.1107/S0907444909052925
21. Vaguine, A.A., Richelle, J. and Wodak, S.J. (1999) SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. Acta Crystallogr. Sect. D Biol. Crystallogr. 55, 191-205 doi:10.1107/S0907444998006684
22. Collaborative Computational Project, Number 4. (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr. Sect. D Biol. Crystallogr. 50, 760-763 doi:10.1107/S0907444994003112
23. Barrett, A.J., Kembhavi, A.A., Brown, M.A., Kirschke, H., Knight, C.G., Tamai, M. et al. (1982) L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem. J. 201, 189-198 doi:10.1042/bj2010189
24. Morrison, J.F. (1969) Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 185, 269-286 doi:10.1016/0005-2744(69)90420-3
25. Dixon, M. (1953) The determination of enzyme inhibitor constants. Biochem. J. 55, 170-171 doi:10.1042/bj0550170
26. Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T. et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749 doi:10.1021/jm0306430
27. McGrath, M.E., Klaus, J.L., Barnes, M.G. and Bromme, D. (1997) Crystal structure of human cathepsin K complexed with a potent inhibitor. Nat. Struct. Biol. 4, 105-109 doi:10.1038/nsb0297-105
28. McGrath, M.E. (1999) The lysosomal cysteine proteases. Annu. Rev. Biophys. Biomol. Struct. 28, 181-204 doi:10.1146/annurev.biophys.28.1.181
29. Li, C.S., Deschenes, D., Desmarais, S., Falgueyret, J.-P., Gauthier, J.Y., Kimmel, D.B. et al. (2006) Identification of a potent and selective non-basic cathepsin K inhibitor. Bioorg. Med. Chem. Lett. 16, 1985-1989 doi:10.1016/j.bmcl.2005.12.071
30. Krissinel, E. and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 doi:10.1016/j.jmb.2007.05.022
31. Kawabata, T. (2010) Detection of multiscale pockets on protein surfaces using mathematical morphology. Proteins: Struct. Funct. Bioinf. 78, 1195-1211 doi:10.1002/prot.22639
32. Mullard, A. (2016) Merck & Co. drops osteoporosis drug odanacatib. Nat. Rev. Drug Discovery 15, 669 doi:10.1038/nrd.2016.207
33. Runger, T.M., Adami, S., Benhamou, C.-L., Czerwinski, E., Farrerons, J., Kendler, D.L. et al. (2012) Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J. Am. Acad. Dermatol. 66, e89-e96 doi:10.1016/j.jaad.2010.11.033
34. Eastell, R., Nagase, S., Small, M., Boonen, S., Spector, T., Ohyama, M. et al. (2014) Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J. Bone Miner. Res. 29, 458-466 doi:10.1002/jbmr.2047
35. Eastell, R., Nagase, S., Ohyama, M., Small, M., Sawyer, J., Boonen, S. et al. (2011) Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J. Bone Miner. Res. 26, 1303-1312 doi:10.1002/jbmr.341
36. Li, F., Lu, J., Cheng, J., Wang, L., Matsubara, T., Csanaky, I.L. et al. (2013) Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat. Med. 19, 418-420 doi:10.1038/nm.3104
37. Bhatia, S., Daschkey, S., Lang, F., Borkhardt, A. and Hauer, J. (2016) Mouse models for pre-clinical drug testing in leukemia. Expert Opin. Drug Discovery 11, 1081-1091 doi:10.1080/17460441.2016.1229297
38. Xu, D., Nishimura, T., Nishimura, S., Zhang, H., Zheng, M., Guo, Y.-Y. et al. (2014) Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med. 11, e1001628 doi:10.1371/journal.pmed.1001628
39. McKenzie, R., Fried, M.W., Sallie, R., Conjeevaram, H., Di Bisceglie, A.M., Park, Y. et al. (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333, 1099-1105 doi:10.1056/NEJM199510263331702
40. Lecaille, F., Chowdhury, S., Purisima, E., Bromme, D. and Lalmanach, G. (2007) The S2 subsites of cathepsins K and L and their contribution to collagen degradation. Protein Sci. 16, 662-670 doi:10.1110/ps.062666607
41. Dossetter, A.G., Beeley, H., Bowyer, J., Cook, C.R., Crawford, J.J., Finlayson, J.E. et al. (2012) (1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis. J. Med. Chem. 55, 6363-6374 doi:10.1021/jm3007257
42. Gauthier, J.Y., Chauret, N., Cromlish, W., Desmarais, S., Duong Le, T., Falgueyret, J.-P. et al. (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg. Med. Chem. Lett. 18, 923-928 doi:10.1016/j.bmcl.2007.12.047